title: Urinary bladder hyperplasia in the rat: non-specific pathogenetic considerations using a beta-lactam antibiotic.
abstract: Eight of the known chemical substances associated with neoplasia in man are known to target the urinary bladder urothelium. Preneoplastic changes have been identified following exposure to each of these chemicals, and they have also been seen to occur in many species of lab animals. The most important such change is preneoplastic hyperplasia. Adaptive hyperplasia is the first form of hyperplasia to appear. It can be seen both in untreated controls and dosed animals. The distinguishing features are that in treated groups it does not progress with dose or time, and the process is reversible. Reparative hyperplasia involves disruption of homeostasis. Its severity increases with dose and time. It is not seen in controls but it is still reversible during the recovery segment after exposure to a toxic substance. When reparative hyperplasia continues beyond a certain threshold of time and dose, it progresses to preneoplastic hyperplasia, which further progresses with continued stimulation to frank neoplasia. The synthetic beta-lactam penem antibiotic FCE 22891 and its metabolite FCE 22101 caused adaptive urothelial hyperplasia of the urinary bladder only in rats and in no other species. Based on the pharmacokinetic profile of FCE 22891 and FCE 22101, it can be deduced that the morphologic finding of adaptive urothelial hyperplasia is caused by reduction of intravesicular urine pH. This effect has no relevance to therapeutic use in humans. Further, it is important to distinguish adaptive and reparative hyperplasia in preclinical toxicity studies.
authors.affiliation: American Health Foundation, NY.
authors.forename: M J
authors.initials: MJ
authors.lastname: Iatropoulos
authors.forename: A J
authors.initials: AJ
authors.lastname: Newman
authors.forename: A D
authors.initials: AD
authors.lastname: Dayan
authors.forename: M
authors.initials: M
authors.lastname: Brughera
authors.forename: G
authors.initials: G
authors.lastname: Scampini
authors.forename: G
authors.initials: G
authors.lastname: Mazue
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000633:toxicity*; D015780:Carbapenems / Q000633:toxicity*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D006863:Hydrogen-Ion Concentration; D006965:Hyperplasia / Q000139:chemically induced / Q000473:pathology; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D007769:Lactams; D008297:Male; D011230:Precancerous Conditions / Q000473:pathology; D051381:Rats; D013997:Time Factors; D001743:Urinary Bladder / Q000187:drug effects / Q000473:pathology*; D001745:Urinary Bladder Diseases / Q000139:chemically induced* / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000473:pathology; D014556:Urine / Q000502:physiology; D047090:beta-Lactams
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D007769:Lactams; D047090:beta-Lactams; C041561:FCE 22891; C040033:ritipenem